RTP Mobile Logo
Select Publications

Borghaei H et al. Phase 1 updated exploration and first expansion data for DLL3-targeted T-cell engager tarlatamab in small cell lung cancer. IASLC 2022;Abstract OA12.05.

Calles A et al. A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study. ASCO 2022;Abstract 8581.

Cheng Y et al. Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. ASCO 2022;Abstract 8505.

Haridas CS et al. Recent stage shifts and changes in the treatment of stage I small cell lung cancer in the United States. IASLC 2022;Abstract EP14.05-003.

Knelson EH et al. PARP inhibitors in small-cell lung cancer: Rational combinations to improve responses. Cancers (Basel) 2021;13(4):727. Abstract

Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39(6):619-30. Abstract

Navarro A et al. Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial. ASCO 2022;Abstract 8524.

Owonikoko TK et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol 2021;39(12):1349-59. Abstract

Patel S et al. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther Adv Med Oncol 2021;13:17588359211020529. Abstract

Paz-Ares L et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open 2022;7(2):100408. Abstract

Rudin CM et al. First-line pembrolizumab or placebo combined with etoposide and platinum for ES-SCLC: KEYNOTE-604 long-term follow-up results. IASLC 2022;Abstract OA12.06.

Rudin CM et al. SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). ASCO 2022;Abstract LBA8507.

Sands J et al. KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer. ASCO 2022;Abstract TPS8606.

Sands J et al. Lung screening benefits and challenges: A review of the data and outline for implementation. J Thorac Oncol;16(1):37-53. Abstract

Singh AK, Sands JM. Yet another reminder of the value of lung cancer screening. J Thorac Oncol 2021;16(9):1437-9. Abstract

Spigel DR et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. Ann Oncol 2021;32(5):631-41. Abstract

Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract

Wang J et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022;23(6):739-47. Abstract

Weiss J et al. Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: Pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 2021;22(5):449-60. Abstract